

Index

a

activation-induced marker expression 247

active immunization 285

adaptive immune system

- antigen-specific T cells 168, 202–203, 210, 212, 213, 362
- B cells, development of 204–205
- diversity of 201–202
- somatic hypermutations 205–206
- T-cell phenotypes and functions 203–204, 209
- T-follicular helper (TFH) 204, 247, 269, 338
- T-helper cells, antigen-specific 209
- T-helper type 1 (Th1) 278

alkaline technique 179

alphavirus-based expression 111

alphavirus-based replicon RNA (repRNA) 131, 292, 315

altered peptide ligand (APL) vaccination 216

anti-reverse cap analogs (ARCA) 44, 355

antibody-dependent cellular cytotoxicity (ADCC) 206, 269

antigen-presenting cells (APCs) 8, 29, 31, 91, 205, 214, 269, 327, 337, 340

antigen-specific T cells 168, 202, 203, 210–213, 362

antimicrobial resistance (AMR) 329

antiretroviral therapy (ART) 267

apolipoprotein B 11, 208, 210, 211

atherosclerosis

- antigen-specific T-helper cells in 209
- autoimmune component of 208–209
- B cells and autoantibodies in 209–210
- Beta-2-glycoprotein I 211
- heat-shock proteins (HSPs) 211
- LDL-C 210–211
- vascular endothelial growth factor (VEGF) 213
- virus-derived antigens 211–212

autoimmune diseases

- break of tolerance 206–207
- immunomodulation of 207–208
- mRNA-based peptide vaccination strategies in 218–219

autoimmune encephalomyelitis 216–218

autoimmunity 201–208, 211–217, 220, 223, 225

b

bacillus Calmette–Guérin (BCG) 325

B cells

- development of 204–205
- noncanonical functions of 206
- somatic hypermutations of 205–206

blood-feeding arthropods 285

BNT162b2 3, 8, 11, 14, 15, 29, 30, 33–35, 43, 46, 48, 52, 53, 85, 128, 164, 181, 243, 244, 247–249, 252, 311

booster immunizations 130, 139, 142, 251–252, 262, 272, 273

Borrelia burgdorferi 288, 290, 308

broadly neutralizing antibodies
(bNAbs) 260

C

cancer

immunotherapy 47, 130, 267,
337–339, 343, 364

mRNA vaccines 89–90

tumor-specific antigens 342

vaccination 339, 346–349

cap 35–37, 188

CleanCap technology 43, 181, 355,
356, 364

homeostasis 37

7-methyl guanosine (m7G) 354, 355

capping 35, 37, 42–45, 180, 181, 187,
188, 353–355

caspase activation and recruitment
domain (CARD) 31

caspase recruitment domain-containing
protein 15 (CARD15) 31

cationic nanoemulsion delivery 270

CD4⁺ T cells 203–204, 210–212, 218,
247, 269, 270, 316, 327, 328, 337,
338

activation of 327, 328

responses 273, 276, 278

CD8⁺ T cells 15, 30, 31, 35, 48, 53, 122,
125, 130, 138, 141, 142, 203, 204,
206, 211, 220, 247, 249–251, 267,
276, 278, 314–316, 327–329, 337,
338, 340, 343–345, 357, 360, 361,
367, 368, 370

activation 53, 278, 327

responses 15, 48, 122, 125, 130, 138,
141, 247, 250, 267, 269, 276, 292,
306, 307, 311, 348, 364

CD40 205, 267, 268, 327, 342, 345, 361,
366, 368

Chagas disease 305, 311, 316–317

circRNAs

biogenesis of 162

ElciRNAs 162

exonic circRNA 163

intronic circRNA 163

physiological functions of 162–163

protein enzymatic RNA circularization
165

vaccine 168, 169

closed-loop model 35, 39, 40

coding sequence 37, 39, 41–42, 74, 86,
88, 307, 357, 364

complement activation-related

pseudoallergy (CARPA) 48

COVID-19

pandemic 3, 14, 52, 128, 243–253, 289,
307, 310, 326, 328, 329, 331

vaccines 84–89

Crimean–Congo hemorrhagic fever virus
(CCHFV) 286, 291–292

crossflow filtration 182

CVD autoimmunity 212–215

CVnCoV 249–250

cyclic GMP–AMP (cGAMP) 162

cytosolic nonself RNA sensors 31, 34

cytotoxic genes 139

cytotoxic T lymphocytes (CTLs) 15, 30,
31, 35, 48, 53, 122, 125, 130, 138,
141, 142, 203, 204, 206, 211, 220,
247, 249–251, 267, 276, 278,
314–316, 327–329, 337, 338, 340,
343–345, 357, 360, 361, 367, 368,
370

d

damage-associated molecular patterns
(DAMPs) 32

dendritic cells (DCs) 267, 327, 341

1,2-dioleoyl-3-dimethylammonium
propane (DODAP) 10

1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP) 360

1,2-dioleoyl-sn-glycero-3-phosphoethanol-
amine (DOPE) 360

1,2-di-*O*-octadecenyl-3-trimethyl-
ammonium propane (DOTMA)
10, 360

direct *in vivo* mRNA delivery 265,
267–269

- DNA replicon system 111
 DNA replicon vectors 111, 121, 126, 138
 DNA–RNA hybrid formation 181
 DNA vaccination 212–214
 doggybone DNA (dbDNA) 179
 DOTMA/DOPE liposomes 13
 dynamic light scattering 188
- e**
 Ebola virus (EBOV) 122
 engineered gp120 outer-domain probe (eOD-GT8) 273
 Env-Gag VLP optimization 277
- f**
 fill-to-finish 186
- g**
 good manufacturing practices (GMP) 75, 190, 309
 guide RNA 71, 73, 74, 78
- h**
 H/ACA snoRNP 71–73
 heat shock proteins (HSPs) 211, 356
 helminths 303, 313, 317
 high-pressure liquid chromatography (HPLC) 45, 167, 182, 188
 HIV-1 260–261
 mRNA-based vaccines 263–271
 homeodomain interacting protein kinase 2 (HIPK2) gene 162
 human leukocyte antigen (HLA) 220, 316, 337
Hyalomma genus ticks 292
 hydrogen bond donor 70, 77, 83, 84
- i**
 IFN-stimulated genes (ISGs) 32
 immunologic adjuvants modulate 222
 immunostimulatory genes 109, 130, 131, 139, 140, 143
 immunotherapy
 with immunoglobulins 214–215
- TCR/CAR T-cell 215
 incomplete Freund's adjuvant (IFA) 221, 222, 343
 innate immune response
 in humans 33–34
 in mice 34–35
 interferon-gamma release assay (IGRA) 331
 internal ribosome entry site (IRES) 7, 162
 intracellular cytokine staining 247
 intramuscular (IM) administration 14, 29, 121, 123, 125, 126
in vivo mRNA delivery 265, 267–269
in vitro transcription (IVT)
 production 42–44
 reaction 71, 73–75, 80–82, 84, 180–184, 289
 of RNA, 74–75
 stage 180
 irreversible electroporation (IRE) 142
Ixodes cookei 291
Ixodes scapularis 286, 290, 291
- k**
 Kunjin virus (KUN) expression systems 111
- l**
 Langat virus 291
 leishmaniasis 130, 305, 311, 315, 316
 lipid nanoparticles (LNP) 11, 269, 270, 290
 industrial standards 186
 and mRNA encapsulation 185–186
 systemic delivery of nucleic acids 10–12
 lipoarabinomannan (LAM) 326
 lipopolyplex 170
 lithium chloride 182
 low-density lipoprotein cholesterol (LDL-C) 208, 210, 211
 Lyme disease 286, 288, 308
 LYMERix 288

m

major histocompatibility complex class II (MHC class II) 327

dependent autoimmunity 208

variability 222

malaria 130, 292, 293, 303–318

Measles virus 113

migration inhibitory factor (MIF) 313

mitochondrial antiviral signaling protein (MAVS) 31

mix-and-match approach 129

monophosphoryl lipid A (MPLA) 345

mRNA-1273 3, 8, 11, 14, 29, 34, 46, 48, 51, 52, 85, 128, 164, 243, 247–248, 252

mRNA

- adjuvants for 366–368
- clinical application 368–373
- delivery and formulation 358–362, 365
- innate immune sensing 362–365
- IVT 42–44
- manufacturing and design 353–358
- posttranscriptional modification 44–45
- purification, of IVT 45

mRNA capping 35, 37, 42–45, 180, 181, 187, 188, 353–355

mRNA pseudouridylation

- of sense codons decoding 80
- on nonsense suppression 78–80

mRNA-transduced dendritic cells 265, 267

mucosal delivery 54, 276

multiangle light scattering 188

multiple array antigen presentation 277–278

multiple sclerosis (MS)

- antigen-specific immunity in 215–216

mutation-guided vaccines 262

Mycobacterium tuberculosis (Mtb)

- (pre-)clinical development 330–332
- primary TB 325
- protective immunity against 326–328
- suitability and advantages of 328–330

n

neoantigens 344

neutralizing antibodies (nAbs) 41, 49, 85, 87, 88, 113, 121, 124, 125, 127–130, 137, 244, 247–251, 259, 260, 269, 270, 273, 274, 276–278, 285, 291, 306, 328

NMD pathway 80

N1-methyl- Ψ 70, 74, 75, 77, 82–91, 354

Nobivac-Lyme 288

nucleoside modifications 14, 32, 44, 69, 77, 90, 164, 177, 307, 310

o

2',5'-oligoadenylate synthetase (OAS) 32

oncolytic viruses 131, 140–143

open reading frame (ORF) 6, 41, 164, 352, 354, 355

Orthopneumoviruses 127

OspA-based protein vaccines 288

outer-surface protein A (OspA) 288

p

parasitic infections 303–305

- Chagas disease 316–317
- helminths 313, 317
- leishmaniasis 315–316
- malaria 311–314
- prevalence 304–305
- toxoplasmosis 315–316
- vaccine development 305–307

passive immunoprophylaxis 260

pathogen-associated molecular patterns (PAMPs) 30, 201, 326, 341

pattern recognition receptors (PRRs) 30, 201, 326, 344

peptide vaccine 212, 216, 218–227

Plasmodium falciparum circumsporozoite protein (PfCSP) 292–293

phage polymerases 5

plasmid DNA (pDNA) 111, 112, 120, 124–126, 130, 131, 137, 139, 179, 353

plasmid DNA production 178–180

Plasmodium sporozoite 293

- poly(A) polymerases 39–41
poly-A-binding protein (PABP) 39
polyethyleneiminstearic acid (PSA) 268
posttranscriptional modification 8, 44, 45, 51
Powassan virus 286, 289, 291
premembrane (prM) protein 291
pre-mRNA splicing 35, 77–80
preferentially expressed antigen in melanoma (PRAME) 369
prostate-specific membrane antigen (PSMA) 138
protein/RNA interaction 39
protein translation 45, 77–80, 161, 163, 250, 315
pseudouridine 44
 the Fifth Nucleoside 69–70
 immune system 80–82
 pre-mRNA splicing and protein translation 77–80
 RNA detection 75–77
pseudouridine synthase (PUS1) 71, 73, 79
Ψ detection, RNA
 direct Ψ sequencing methods 76–77
 indirect Ψ sequencing methods 76
purification, of IVT mRNA 45
PUS enzymes 71
- r**
RABV system 113
receptor-binding domain (RBD) 88, 168, 244
relapsing fever 286
replication deficient system 111
replication proficient system 110, 111
Replicon-based RNA vaccine platform 292
reporter gene expression 131
Rhabdovirus expression systems 112
ribonucleoproteins (RNPs) 35, 38, 71, 72
Ribozymes 112, 167, 188
RNA-binding proteins (RBP) 35, 37, 38, 77
RNA administartion methods
 direct in vivo mRNA delivery 265, 267–269
 in vivo mRNA delivery 265, 267–269
 intramuscular (IM) administration 14, 29, 121, 123, 125, 126
RNA delivery
 biological cell membranes to liposomal drugs 8–10
 ionizable lipid nanoparticles 10–12
RNA-dependent pseudouridylation 71–73
RNA-guided pseudouridylation 72–74
RNA-independent pseudouridylation 71
RNA-lipoplexes (RNA-LPX) 217, 218
RNA polymerase enzyme 178
RNA/protein interaction 35, 37, 38, 77
RNA pseudouridylation
 artificially 73–75
 naturally 71–73
RNA stabilization 265
rRNA 71–72, 77–78, 83, 91
- S**
Salp14 290
Ψ sequencing methods 76, 77
severe acute respiratory syndrome
 coronavirus 2 (SARS-CoV2)
 BNT162b2–Pfizer/BioNTech 248–249
 mRNA-1273–Moderna 247–248
selective organ targeting (SORT) strategy 47
self-amplifying mRNA 88, 89, 244, 251, 267, 270–271, 315
self-assembling nanoparticles 274, 275, 277
self-replicating RNA
 against infectious diseases 114–120
 expression systems for 109–113
 vaccines against cancers 130–143
 vaccines against infectious diseases 113–130
signal transducer and activator of transcription 3 (STAT3) 345

- simian–human immunodeficiency virus (SHIV) 260, 270
- single-cell universal polyA-independent RNA sequencing (SUPeR-seq) 161
- single-chain antibody (scFv) 142, 293
- single-chain variable fragments (scFv) 215
- single-stranded RNA (ssRNA) 7, 30, 82, 89, 109, 165
- slow delivery 276–277
- small interfering RNA (siRNA) 11, 366
- therapeutics 46
- small nucleolar ribonucleoproteins (snoRNPs) 71
- soft ticks 286
- somatic hypermutation (SHM) 205–206, 275
- spliceosome 77
- Staggered herringbone mixer 186
- stem-loop binding protein (SLBP) 39
- stimulator of interferon genes (STING) pathway 162, 344
- supplemental adjuvants 278
- synthetic circRNAs
- application of 168–169
 - approaches to 164–167
 - delivery systems of 170
 - design considerations of 163–164
- synthetic long peptide (SLP) 344
- t**
- tangential flow filtration techniques 45, 179
- T cells
- activation 8, 29, 53, 278, 327, 350, 353, 364, 366, 368
 - CD4⁺ T cells 203–204, 210–212, 218, 247, 269, 270, 316, 327, 328, 337, 338
 - CD8⁺ T cells 15, 30, 31, 35, 48, 53, 122, 125, 130, 138, 141, 142, 203, 204, 206, 211, 220, 247, 249–251, 267, 276, 278, 314–316, 327–329, 337, 338, 340, 343–345, 357, 360, 361, 367, 368, 370
 - phenotypes and functions 203–204
- T-follicular helper (TFH) 204, 247, 269, 338
- T-helper cells, antigen-specific 209
- T-helper type 1 (Th1) 278
- thin-layer chromatography (TLC) 69
- tick-borne diseases
- Ixodes scapularis* 286
 - mRNA vaccine 288–291
 - Powassan virus 291
 - RNA vaccine against Crimean–Congo hemorrhagic fever virus 291–292
 - tick saliva antigens as 286–288
 - tick's life cycle 286
 - vector-borne diseases 285–286
- tick-borne flaviviruses 291
- tick immunity 289, 290, 293
- tick lectin pathway inhibitor (TSLPI) 290
- tick salivary antigens 286–290
- tick salivary proteins 290
- tissue-resident memory cell (T_{RM}) 203, 276, 314, 349
- tolerogenic peptide vaccination 212
- toll-like receptor (TLR) 2, 7, 30, 81, 201, 217, 278, 326, 342
- toxoplasmosis 305, 311, 314–315
- trans-amplifying RNA (taRNA) 127
- tRNA 37, 41–42, 44, 71, 77–78, 81, 83, 87
- tuberculosis (TB) 325
- tumor
- cancer immunotherapy 337–339
 - mediated immunosuppression 349–350
- tumor antigens 13, 215, 337, 339–343, 370
- tumor-associated antigens 109, 131–139, 337
- u**
- U-to-Ψ isomerization 69–71
- unmodified mRNA vaccines 69–92

untranslated regions (UTR) 6, 37–39,
162, 307, 354

v

vaccine administration routes 348
vector-borne diseases 285–286
viral replicon particles (VRPs) 270
virus derived antigens 211–212
VLP-forming platform 272, 274

VSV system 113, 128, 140

VSV–ZEBOV particles 123

w

Watson–Crick base pairing 41, 70, 78, 83

y

Yamanaka reprogramming factors 82













